Trial Status
19th March 2009
UK Study status
8 of the 23 people who have agreed to take part in the Allegro study in the UK have now completed the first 12 months of the treatment period.
An analysis of the data will be made later this year to assess whether the study treatment period will need to be 24 or 30 months. Details will be released in due course.
At the end of the study (24 or 30 months of treatment), everyone who completed the Allegro study will be invited to enter into a separate 12 month extension study. During this extension study, only laquinimod drug will be given (not placebo).
If you have any questions regarding the Allegro study, please contact your study team.
12th February 2009
Teva Pharmaceutical Industries Ltd. announced that oral laquinimod, an investigational treatment for relapsing-remitting multiple sclerosis (RRMS), has received a Fast Track designation from the U.S regulatory agency, the Food and Drug Administration (FDA).
Drugs that receive 'Fast Track' status are intended for the treatment of serious conditions and that have demonstrated the potential to address unmet medical needs.
17th November 2008
Globally, 1000 patients with RRMS have agreed to participate in the Allegro study and therefore recruitment has now completed.
It has taken one year to recruit the 1000 participants who will each take part in the trial for either two years or two 1/2 years. It is anticipated that the results of the Allegro study will be available sometime during 2011.
Other countries taking part in the Allegro study in addition to the UK include the US and Canada, Germany, Italy, France, Spain, Netherlands, Hungary, Sweden, Russia, Ukraine and Poland.